USP1, in particular, has been identified as a promising target for cancer‐therapy, for a variety of tumours, including: breast (Lim et al, 2018; Ma et al, 2018; Mussell et al, 2020; Niu et al, 2020), ovarian (Lim et al, 2018; Sonego et al, 2019), colorectal (Xu et al, 2019), Non‐small Cell Lung (Chen et al, 2011), bone (Williams et al, 2011) and glioma (Ma et al, 2019) cancers. Here, USP1 is linked to cancer.